DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026.
“We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger foundation for sustainable growth and long-term value creation.”
Third-Quarter 2026 Companywide Financial Results
Unless otherwise noted, all financial results reflect continuing operations and exclude Baxter’s former Kidney Care business, which is reported as discontinued operations.
Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s segments.
Third-Quarter 2026 Segment Results
Beginning in the second quarter of 2026, Baxter updated its segment reporting structure to align with changes to the company’s operating model.4 Previously reported segment results have been recast to conform to the updated reporting structure and are available on the Investor Relations section at www.baxter.com. In the third quarter, growth continued across all segments and divisions.
Full-Year 2026 Financial Outlook
The company raised its full-year financial outlook:
See the "Non-GAAP Financial Measures" section for explanations of the company’s non-GAAP financial measures.
Earnings Conference Call
Baxter will host a conference call today, Oct. 29, 2026, at 7:30 a.m. CDT to discuss its third-quarter 2026 results and provide an update on the business. The conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com. Please see www.baxter.com for more information regarding this and future investor events and webcasts.
Upcoming Webcasted Investor Events (to be made available on www.baxter.com)
About Baxter
At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Non-GAAP Financial Measures
Non-GAAP financial measures may enhance an understanding of the company's operations and may facilitate an analysis of those operations, particularly in evaluating performance from one period to another. Management believes that non-GAAP financial measures, when used in conjunction with the results presented in accordance with U.S. GAAP and the company's reconciliations to corresponding U.S. GAAP financial measures (which are included in the tables accompanying this release), may enhance an investor’s overall understanding of the company's past financial performance and prospects for the future. Management uses these non-GAAP measures internally in financial planning, to monitor business unit performance, and, in some cases, for purposes of determining incentive compensation. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP.
Organic sales growth is a non-GAAP measure that excludes the impact of the Kidney Care MSA not reflected in reportable segments, impacts associated with business acquisitions or divestitures, and is calculated on a constant currency basis, as if foreign currency exchange rates had remained constant between the prior and current periods.
Other non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide the company's detailed reconciliations to the corresponding U.S. GAAP financial measures) are: adjusted gross margin; adjusted selling, general and administrative expenses; adjusted research and development expenses; adjusted other operating income, net; adjusted operating income (loss); adjusted other income (expense), net; adjusted income (loss) from continuing operations before income taxes; adjusted income tax expense (benefit); adjusted income (loss) from continuing operations; adjusted income (loss) from discontinued operations; adjusted net income (loss); adjusted net income (loss) attributable to Baxter stockholders; adjusted diluted earnings per share from continuing operations; adjusted diluted earnings per share from discontinued operations; and adjusted diluted earnings per share. Those non-GAAP financial measures exclude the impact of special items. For the quarters and nine-month periods ended September 30, 2026 and 2025, special items for one or more periods included intangible asset amortization, business optimization charges, acquisition and integration costs, separation-related costs, expenses related to European medical devices regulation, certain legal matters, investment impairments, product-related items, business transformation costs, the gain on debt extinguishment, the gain on the sale of the Kidney Care business, Hurricane Helene costs, and certain tax matters. These items are excluded because they are highly variable or unusual and of a size that may substantially impact the company's reported operations for a period. Additionally, intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and the company's Board of Directors assess performance.
This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures. Free cash flow is used by management and the company's Board of Directors to evaluate the cash generated from Baxter's operating activities each period after deducting its capital spending.
This release also includes forecasts of certain of the aforementioned non-GAAP measures on a forward-looking basis as part of the company's financial outlook for upcoming periods. Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic sales growth represents the company's targeted future sales growth excluding sales to Vantive under the Kidney Care MSA not reflected in reportable segments, reflects impacts associated with business acquisitions or divestitures, and assumes foreign currency exchange rates remain constant in future periods. Additionally, forward-looking adjusted diluted EPS guidance excludes potential charges or gains that would be reflected as non-GAAP adjustments to earnings. Baxter provides forward-looking organic sales growth guidance and adjusted diluted EPS guidance because it believes that these measures provide useful information for the reasons noted above. Baxter has not provided reconciliations of forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, separation-related costs, business transformation costs, asset impairments and unusual gains and losses, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K). In addition, Baxter believes that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
Forward-Looking Statements
This release includes forward-looking statements concerning the company’s financial results (including the updated outlook for full-year 2026) and certain product development activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: there is substantial competition in the product markets in which the company operates and the risk of declining demand and pricing pressures could adversely affect the company’s business, results of operations, financial condition and cash flows; the company may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology; global economic conditions, including inflation, have adversely affected, and could continue to adversely affect, the company’s operations; the company is subject to risks associated with doing business globally, including changes in tariffs and trade policies and treaties (including with respect to the validity of previously issued tariffs and the availability of any related refunds) as well as the ongoing Iran conflict and other geopolitical events; the company may not achieve its financial goals; the company’s operating results and financial condition have fluctuated and may in the future continue to fluctuate; the company is exposed to risks as a result of its previously completed strategic actions; the company may not achieve the anticipated benefits of its significant transactions, including the sale of its Kidney Care business and its acquisition of Hill-Rom Holdings, Inc.; the company may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions; the company has experienced and may continue to experience issues with quality management or product quality, including with respect to the Novum IQ large volume pump and a recently issued U.S. Food and Drug Administration Warning Letter; the company has experienced disruptions in its supply chain and may experience additional disruptions in the future; the company has experienced and may continue to experience manufacturing, sterilization, supply, or distribution difficulties; the company may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price; the company’s significant indebtedness requires it to use a substantial amount of its cash flow for debt service and constrains the company’s ability to pursue growth strategies and advance its R&D capabilities; continued consolidation in the health care industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate the company’s ability to sell to certain of its significant market segments; segments of the company’s business are significantly dependent on major contracts with group purchasing organizations, integrated delivery networks, and certain other distributors and purchasers; management transition creates uncertainties, and the company may experience difficulties in managing such transitions, including attracting and retaining key employees; changes in foreign currency exchange rates and interest rates have had, and may in the future have, an adverse effect on the company’s results of operations, financial condition, cash flows, and liquidity; future material impairments in the value of the company’s goodwill, intangible assets, and other long-lived assets would negatively affect the company’s operating results; the company has experienced and may in the future experience breaches and other incidents affecting its information technology systems or protected information, including from obsolescence, cyber security breaches and data leakage; the company is exposed to risks associated with incorporating artificial intelligence (AI), machine learning and other emerging technologies into our products, services and operations; a portion of the company’s workforce is unionized, and the company could face labor disruptions that would interfere with its operations; the effects of climate change, including evolving legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect the company’s business, results of operations, financial condition, and cash flows; the company’s goals, activities, and disclosures related to sustainability and corporate responsibility matters, and the perception of the company’s activities in these areas, may fail to satisfy the differing expectations of key stakeholders on these matters; the company is subject to laws and regulations globally, and its failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company; if reimbursement or other payment for our current or future products is reduced or modified in the U.S. or in foreign countries, or there are changes to policies with respect to pricing, taxation, or rebates, the company’s business could suffer; increasing regulatory focus on, and expanding laws relating to, privacy, AI, and cybersecurity could impact the company’s business and expose it to increased liability; the company is party to a number of pending lawsuits and other disputes which may adversely impact it; changes in tax laws or exposure to additional income tax liabilities may have a negative impact on the company’s operating results; the company could be subject to fines or damages and possible exclusion from participation in federal or state healthcare programs if it fails to comply with the laws and regulations applicable to its business; if the company is unable to protect or enforce its patents or other proprietary rights, or if the company becomes subject to claims or litigation alleging infringement of the patents or other proprietary rights of others, the company’s competitiveness and business prospects may be materially damaged; the company’s Amended and Restated Bylaws could limit its stockholders’ ability to choose their preferred judicial forum for disputes with the company or its directors, officers, or employees; the company decreased its quarterly dividend to $0.01 per share and cannot guarantee that it will increase the amount of dividends it pays, or that it will not cease paying dividends, in the future; the company’s common stock price has fluctuated significantly and may continue to do so; and other risks discussed in Baxter’s most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.
Baxter is a trademark of Baxter International Inc.
| _____________________________ |
1 Sales growth on an organic basis and adjusted diluted EPS are non-GAAP financial measures. See the “Non-GAAP Financial Measures” section below for information about the non-GAAP financial measures included in this release and see the accompanying tables to this press release for reconciliations of those non-GAAP measures to the corresponding U.S. GAAP measures. |
2 Organic sales growth excludes the impact of the Kidney Care Manufacturing and Supply Agreement (Kidney Care MSA) not reflected in reportable segments, impacts associated with business acquisitions or divestitures, and is calculated at constant currency rates. |
3 Generally Accepted Accounting Principles |
4 The former Pharmaceuticals segment is now reported within the Infusion Therapies & Platforms (ITP) division of the Medical Products & Therapies (MPT) segment. Additionally, sales of products and services provided directly through certain of the company's manufacturing facilities related to ITP that were previously reported in Other, are now reported in the ITP division of its MPT segment. The remaining Other sales not allocated to a segment consist of sales to Vantive Health LLC (Vantive), pursuant to the related Kidney Care MSA. |
| BAXTER INTERNATIONAL INC.
Consolidated Statements of Income (Loss) (unaudited) (in millions, except per share and percentage data) | |||||||||
|
Three Months Ended
|
|
| ||||||
|
| 2026 |
|
|
| 2025 |
|
| Change |
NET SALES | $ | 2,976 |
|
| $ | 2,835 |
|
| 5% |
COST OF SALES |
| 1,982 |
|
|
| 1,885 |
|
| 5% |
GROSS MARGIN |
| 994 |
|
|
| 950 |
|
| 5% |
% of Net Sales |
| 33.4 | % |
|
| 33.5 | % |
| (0.1) pts |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES |
| 730 |
|
|
| 708 |
|
| 3% |
% of Net Sales |
| 24.5 | % |
|
| 25.0 | % |
| (0.5) pts |
RESEARCH AND DEVELOPMENT EXPENSES |
| 125 |
|
|
| 118 |
|
| 6% |
% of Net Sales |
| 4.2 | % |
|
| 4.2 | % |
| 0.0 pts |
OTHER OPERATING INCOME, NET |
| (86 | ) |
|
| (48 | ) |
| 79% |
OPERATING INCOME |
| 225 |
|
|
| 172 |
|
| 31% |
% of Net Sales |
| 7.6 | % |
|
| 6.1 | % |
| 1.5 pts |
INTEREST EXPENSE, NET |
| 61 |
|
|
| 58 |
|
| 5% |
OTHER (INCOME) EXPENSE, NET |
| (253 | ) |
|
| (7 | ) |
| NM |
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
| 417 |
|
|
| 121 |
|
| NM |
INCOME TAX EXPENSE (BENEFIT) |
| 119 |
|
|
| 172 |
|
| (31)% |
% of Income (loss) from Continuing Operations Before Income Taxes |
| 28.5 | % |
|
| 142.1 | % |
| (113.6) pts |
INCOME (LOSS) FROM CONTINUING OPERATIONS |
| 298 |
|
|
| (51 | ) |
| NM |
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAX |
| (4 | ) |
|
| 5 |
|
| NM |
NET INCOME (LOSS) |
| 294 |
|
|
| (46 | ) |
| NM |
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS |
| — |
|
|
| — |
|
| NM |
NET INCOME (LOSS) ATTRIBUTABLE TO BAXTER STOCKHOLDERS | $ | 294 |
|
| $ | (46 | ) |
| NM |
INCOME (LOSS) FROM CONTINUING OPERATIONS PER COMMON SHARE |
|
|
|
|
| ||||
Basic | $ | 0.58 |
|
| $ | (0.10 | ) |
| NM |
Diluted | $ | 0.57 |
|
| $ | (0.10 | ) |
| NM |
INCOME (LOSS) FROM DISCONTINUED OPERATIONS PER COMMON SHARE |
|
|
|
|
| ||||
Basic | $ | (0.01 | ) |
| $ | 0.01 |
|
| NM |
Diluted | $ | 0.00 |
|
| $ | 0.01 |
|
| NM |
INCOME (LOSS) PER COMMON SHARE |
|
|
|
|
| ||||
Basic | $ | 0.57 |
|
| $ | (0.09 | ) |
| NM |
Diluted | $ | 0.57 |
|
| $ | (0.09 | ) |
| NM |
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING |
|
|
|
|
| ||||
Basic |
| 517 |
|
|
| 514 |
|
|
|
Diluted |
| 520 |
|
|
| 514 |
|
|
|
ADJUSTED OPERATING INCOME (excluding special items)1 | $ | 432 |
|
| $ | 423 |
|
| 2% |
ADJUSTED INCOME (LOSS) FROM CONTINUING OPERATIONS (excluding special items)1 | $ | 303 |
|
| $ | 353 |
|
| (14)% |
ADJUSTED INCOME (LOSS) FROM DISCONTINUED OPERATIONS (excluding special items)1 | $ | (4 | ) |
| $ | 2 |
|
| NM |
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS (excluding special items)1 | $ | 299 |
|
| $ | 355 |
|
| (16)% |
ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS (excluding special items)1 | $ | 0.58 |
|
| $ | 0.69 |
|
| (16)% |
ADJUSTED DILUTED EPS FROM DISCONTINUED OPERATIONS (excluding special items)1 | $ | 0.00 |
|
| $ | 0.00 |
|
| NM |
ADJUSTED DILUTED EPS (excluding special items)1 | $ | 0.58 |
|
| $ | 0.69 |
|
| (16)% |
1 Refer to page 10 for a description of the adjustments and a reconciliation to U.S. GAAP measures.
NM - Not Meaningful | |||||||||
BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions)
The company’s U.S. GAAP results for the three months ended September 30, 2026 included special items which impacted the U.S. GAAP measures as follows: | |||||||||||||||||||||||||||||||||||||||
| Gross Margin | Selling, General and Administrative Expenses | Research and Development Expenses | Other Operating Income, Net | Operating Income (Loss) | Other (Income) Expense, Net | Income (Loss) From Continuing Operations Before Income Taxes | Income Tax Expense (Benefit) | Income (Loss) From Continuing Operations | Net Income (Loss) | Net Income (Loss) Attributable to Baxter Stockholders | Diluted Earnings Per Share from Continuing Operations | Diluted Earnings Per Share | ||||||||||||||||||||||||||
Reported | $ | 994 |
| $ | 730 |
| $ | 125 |
| $ | (86 | ) | $ | 225 |
| $ | (253 | ) | $ | 417 |
| $ | 119 |
| $ | 298 |
| $ | 294 |
| $ | 294 |
| $ | 0.57 |
| $ | 0.57 |
|
Reported percent of net sales (or effective tax rate for income tax expense (benefit)) |
| 33.4 | % |
| 24.5 | % |
| 4.2 | % |
| (2.9 | )% |
| 7.6 | % |
| (8.5 | )% |
| 14.0 | % |
| 28.5 | % |
| 10.0 | % |
| 9.9 | % |
| 9.9 | % |
|
| ||||
Intangible asset amortization |
| 95 |
|
| (50 | ) |
| — |
|
| — |
|
| 145 |
|
| — |
|
| 145 |
|
| 34 |
|
| 111 |
|
| 111 |
|
| 111 |
|
| 0.21 |
|
| 0.21 |
|
Business optimization items1 |
| 45 |
|
| (15 | ) |
| (1 | ) |
| — |
|
| 61 |
|
| — |
|
| 61 |
|
| 15 |
|
| 46 |
|
| 46 |
|
| 46 |
|
| 0.09 |
|
| 0.09 |
|
European medical devices regulation2 |
| 3 |
|
| — |
|
| — |
|
| — |
|
| 3 |
|
| — |
|
| 3 |
|
| 1 |
|
| 2 |
|
| 2 |
|
| 2 |
|
| 0.00 |
|
| 0.00 |
|
Hurricane Helene costs3 |
| 3 |
|
| — |
|
| — |
|
| — |
|
| 3 |
|
| — |
|
| 3 |
|
| — |
|
| 3 |
|
| 3 |
|
| 3 |
|
| 0.01 |
|
| 0.01 |
|
Separation-related costs4 |
| — |
|
| (1 | ) |
| (1 | ) |
| — |
|
| 2 |
|
| — |
|
| 2 |
|
| — |
|
| 2 |
|
| 2 |
|
| 2 |
|
| 0.00 |
|
| 0.00 |
|
Business transformation5 |
| (1 | ) |
| (16 | ) |
| (5 | ) |
| — |
|
| 20 |
|
| — |
|
| 20 |
|
| 5 |
|
| 15 |
|
| 15 |
|
| 15 |
|
| 0.03 |
|
| 0.03 |
|
Legal matters6 |
| — |
|
| (11 | ) |
| — |
|
| 38 |
|
| (27 | ) |
| — |
|
| (27 | ) |
| (7 | ) |
| (20 | ) |
| (20 | ) |
| (20 | ) |
| (0.04 | ) |
| (0.04 | ) |
Gain on debt extinguishment7 |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| 253 |
|
| (253 | ) |
| (58 | ) |
| (195 | ) |
| (195 | ) |
| (195 | ) |
| (0.38 | ) |
| (0.38 | ) |
Tax matters11 |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| (41 | ) |
| 41 |
|
| 41 |
|
| 41 |
|
| 0.08 |
|
| 0.08 |
|
Adjusted | $ | 1,139 |
| $ | 637 |
| $ | 118 |
| $ | (48 | ) | $ | 432 |
| $ | — |
| $ | 371 |
| $ | 68 |
| $ | 303 |
| $ | 299 |
| $ | 299 |
| $ | 0.58 |
| $ | 0.58 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense (benefit)) |
| 38.3 | % |
| 21.4 | % |
| 4.0 | % |
| (1.6 | )% |
| 14.5 | % |
| 0.0 | % |
| 12.5 | % |
| 18.3 | % |
| 10.2 | % |
| 10.0 | % |
| 10.0 | % |
|
| ||||
The company’s U.S. GAAP results for the three months ended September 30, 2025 included special items which impacted the U.S. GAAP measures as follows: | ||||||||||||||||||||||||||||||||||||||||||
| Gross Margin | Selling, General and Administrative Expenses | Research and Development Expenses | Other Operating Income, Net | Operating Income (Loss) | Income (Loss) From Continuing Operations Before Income Taxes | Income Tax Expense (Benefit) | Income (Loss) From Continuing Operations | Income (Loss) From Discontinued Operations, Net of Tax | Net Income (Loss) | Net Income (Loss) Attributable to Baxter Stockholders | Diluted Earnings Per Share from Continuing Operations | Diluted Earnings Per Share from Discontinued Operations | Diluted Earnings Per Share | ||||||||||||||||||||||||||||
Reported | $ | 950 |
| $ | 708 |
| $ | 118 |
| $ | (48 | ) | $ | 172 |
| $ | 121 |
| $ | 172 |
| $ | (51 | ) | $ | 5 |
| $ | (46 | ) | $ | (46 | ) | $ | (0.10 | ) | $ | 0.01 |
| $ | (0.09 | ) |
Reported percent of net sales (or effective tax rate for income tax expense (benefit)) |
| 33.5 | % |
| 25.0 | % |
| 4.2 | % |
| (1.7 | )% |
| 6.1 | % |
| 4.3 | % |
| 142.1 | % |
| (1.8 | )% |
| 0.2 | % |
| (1.6 | )% |
| (1.6 | )% |
|
|
| ||||||
Intangible asset amortization |
| 96 |
|
| (51 | ) |
| — |
|
| — |
|
| 147 |
|
| 147 |
|
| 34 |
|
| 113 |
|
| — |
|
| 113 |
|
| 113 |
|
| 0.22 |
|
| 0.00 |
|
| 0.22 |
|
Business optimization items1 |
| 25 |
|
| (10 | ) |
| (3 | ) |
| — |
|
| 38 |
|
| 38 |
|
| 10 |
|
| 28 |
|
| — |
|
| 28 |
|
| 28 |
|
| 0.05 |
|
| 0.00 |
|
| 0.05 |
|
European medical devices regulation2 |
| 5 |
|
| — |
|
| — |
|
| — |
|
| 5 |
|
| 5 |
|
| 1 |
|
| 4 |
|
| — |
|
| 4 |
|
| 4 |
|
| 0.01 |
|
| 0.00 |
|
| 0.01 |
|
Hurricane Helene costs3 |
| 8 |
|
| — |
|
| — |
|
| — |
|
| 8 |
|
| 8 |
|
| 2 |
|
| 6 |
|
| — |
|
| 6 |
|
| 6 |
|
| 0.01 |
|
| 0.00 |
|
| 0.01 |
|
Separation-related costs4 |
| 1 |
|
| (12 | ) |
| — |
|
| — |
|
| 13 |
|
| 13 |
|
| 3 |
|
| 10 |
|
| — |
|
| 10 |
|
| 10 |
|
| 0.02 |
|
| 0.00 |
|
| 0.02 |
|
Product-related items8 |
| 32 |
|
| — |
|
| — |
|
| — |
|
| 32 |
|
| 32 |
|
| 8 |
|
| 24 |
|
| — |
|
| 24 |
|
| 24 |
|
| 0.05 |
|
| 0.00 |
|
| 0.05 |
|
Acquisition and integration items9 |
| — |
|
| (6 | ) |
| — |
|
| (2 | ) |
| 8 |
|
| 8 |
|
| 2 |
|
| 6 |
|
| — |
|
| 6 |
|
| 6 |
|
| 0.01 |
|
| 0.00 |
|
| 0.01 |
|
Gain on Kidney Care sale10 |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| 37 |
|
| 37 |
|
| 37 |
|
| 0.00 |
|
| 0.07 |
|
| 0.07 |
|
Tax matters11 |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| (213 | ) |
| 213 |
|
| (40 | ) |
| 173 |
|
| 173 |
|
| 0.41 |
|
| (0.07 | ) |
| 0.34 |
|
Adjusted | $ | 1,117 |
| $ | 629 |
| $ | 115 |
| $ | (50 | ) | $ | 423 |
| $ | 372 |
| $ | 19 |
| $ | 353 |
| $ | 2 |
| $ | 355 |
| $ | 355 |
| $ | 0.69 |
| $ | 0.00 |
| $ | 0.69 |
|
Adjusted percent of net sales (or effective tax rate for income tax expense (benefit)) |
| 39.4 | % |
| 22.2 | % |
| 4.1 | % |
| (1.8 | )% |
| 14.9 | % |
| 13.1 | % |
| 5.1 | % |
| 12.5 | % |
| 0.1 | % |
| 12.5 | % |
| 12.5 | % |
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||||||||
Weighted-average diluted shares as reported |
|
|
| 514 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||||
Effect of dilutive securities that were anti-dilutive to dilutive EPS as reported |
| 1 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||||||
Weighted-average diluted shares as adjusted |
|
| 515 |
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||||||||||
Media Contact
Andrea Johnson, (224) 948-5353
media@baxter.com
Investor Contact
Kevin Moran, (224) 948-3085
global_corp_investor_relations@baxter.com
| 2 hours | |
| 8 hours | |
| 11 hours | |
| 11 hours | |
| Oct-21 | |
| Oct-07 | |
| Oct-07 | |
| Sep-30 | |
| Sep-16 | |
| Aug-20 | |
| Aug-20 | |
| Aug-19 | |
| Aug-18 | |
| Aug-18 | |
| Aug-18 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite